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tests rely on the assumption of normal 
distribution,  alternative methods such as 
non-parametric or permutation proce-
dures are needed to derive more accurate 
 P values. Th e trait can also be dichot-
omized on the basis of a predefi ned ACR 
threshold, but this approach generally 
leads to a signifi cant loss of power. Future 
studies that examine kidney pathology 
scores, such as degree of glomeruloscle-
rosis or fi brosis instead of the ACR meas-
urements, may also circumvent this 
problem by providing more powerful 
injury-specifi c phenotypes. Finally, for 
the purpose of testing for signal concord-
ance in humans, a careful selection of 
adequately powered human cohorts with 
disease phenotypes that are closely 
related to those studied in mice is neces-
sary. Because the susceptibilities of mice 
to age-related albuminuria and to dia-
betic nephropathy may have distinctly 
diff erent genetic determination, one can-
not discard the mouse signals that are 
not observed in the human cohort. 
Hopefully, with the increasing number 
of human genome-wide association 
study data sets, more powerful cohorts 
will soon become available to make these 
types of approaches more feasible. Lastly, 
we must remain aware that signifi cant 
associations are not a proof of causality 
but merely represent a screening method 
for identifying genetic variants that war-
rant further research. 
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 commentar y 
 In this issue of  Kidney International , 
Szczech and colleagues 1 report on a  post 
hoc analysis of the Correction of Hemo-
globin and Outcomes in Renal Insuffi  -
ciency (CHOIR) study. 2 Th e original 
study was notable for fi nding increased 
risk of a composite cardiovascular end 
point with epoetin-alfa targeted to a 
hemoglobin (Hgb) level of 13.5 as com-
pared with 11.3 g / dl in patients with 
chronic kidney disease (CKD). When 
this is considered together with the 
CREATE (Cardiovascular Risk Reduc-
tion by Early Anemia Treatment with 
Epoetin Beta) study (CKD patients) 3 
and the Normal Hematocrit Cardiac 
Trial (hemodialysis patients), 4 there was 
a strong trend in each study for 
increased risk for mortality with higher 
Hgb targets during erythropoiesis-
 stimulating agent (ESA) treatment. As a 
result, the National Kidney Foundation ’ s 
Kidney Disease Outcomes Quality Ini-
tiative (KDOQI) anemia guidelines 
were revised in 2007 to include an evi-
dence-based warning to avoid Hgb tar-
gets above 13 g / dl in CKD patients 
treated with ESAs. Little, however, has 
been learned about whether higher Hgb 
targets aff ect certain sub-populations 
diff erently. Th e current elegant analysis 
by Szczech  et al. 1 examines the eff ect of 
Hgb target in the CHOIR study on 
two highly relevant sub-populations, 
CKD patients with diabetes mellitus 
and those with congestive heart 
failure (CHF). 
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 Anemia treatment in chronic 
kidney disease accompanied by 
diabetes mellitus or 
congestive heart failure 
 Steven  Fishbane 1 and  Nobuyuki  Miyawaki 1 
 Anemia is common in chronic kidney disease (CKD). The CHOIR study 
found increased risk of a composite cardiovascular outcome when 
anemia was treated with epoetin-alfa to a target hemoglobin level of 
13.5 as compared with 11.3 g / dl. Whether this increase applies to all 
patient subgroups equally is unclear. We discuss an analysis by Szczech 
and colleagues of the effects of the higher hemoglobin target in CKD 
patients with diabetes mellitus or congestive heart failure. 
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 Before we consider the interesting 
fi ndings of this analysis, one thing must 
be stated clearly. Th e article by Szczech 
 et al. 1 represents a  post hoc observational 
analysis and, while interesting, carries 
little evidentiary weight compared with 
the three major randomized controlled 
trials (RCTs) noted above. Th ese studies 
found trends for increased mortality of 
21 % – 48 % with higher Hgb targets in the 
general CKD population. Th e novel fi nd-
ings of Szczech and colleagues 1 should 
stimulate consideration of causal path-
ways and generate new approaches to 
RCTs to evaluate anemia Hgb targets in 
the sub-populations analyzed. But there 
should be no change at all to current 
ESA treatment in these patients. The 
Hgb target during ESA therapy should 
remain either 10 – 12 or 11 – 12 g / dl 
depending on whether US Food and 
Drug Administration  prescribing instruc-
tions or the KDOQI guidelines are 
used as guidelines. 
 Szczech  et  al .  1 found that  the 
increased risk found in the CHOIR 
study with the higher Hgb target did not 
occur among patients with either dia-
betes mellitus or CHF. An observation 
of this type is always worth testing with 
a question of whether the fi nding is bio-
logically sensible and plausible. Th is 
leads directly to the question of what 
are the causal pathways that explain 
the harm found with higher Hgb 
targets in broader populations. A vari-
ety of hypotheses, all diffi  cult to prove, 
have been suggested, including (1) 
increased blood viscosity, (2) toxic 
eff ects of higher ESA doses, (3) a special 
 vulnerability in ESA-hyporesponsive 
patients, (4) toxicity of additional iron 
treatment requirements, (5) increased 
blood pressure during ESA treatment, 
(6) platelet eff ects, and others. 5,6 Which-
ever of these is the true cause of harm 
with higher Hgb targets, it is diffi  cult to 
see why patients with diabetes or CHF 
would be immune to the harmful 
eff ects. Th ere certainly could, however, 
be some yet-to-be-hypothesized mech-
anism, and continued research is to 
be encouraged. 
 Among patients with diabetes, a 
highly relevant study is the recently 
completed TREAT study (Trial to 
Reduce Cardiovascular Events With 
Aranesp Therapy). This was a 4000-
patient double-blinded RCT that com-
pared darbepoetin treatment to a Hgb 
target of 13 g / dl with placebo among 
patients with diabetes mellitus type 2 
and CKD. Although not a pure test of 
ESA-treated Hgb targets, it is yet another 
study that used ESA therapy to treat to 
a higher-than-typical Hgb target. Th e 
top-line results of this study were 
announced recently, and, most impor-
tantly, there was no statistically signifi -
cant diff erence between the groups in 
cardiovascular outcomes. Th is would 
seem to add external validity to the fi nd-
ings of Szczech  et al. 1 regarding the 
safety of higher Hgb targets in diabetics. 
But one reported result raised concern: 
 “ Among the elements that formed these 
composite endpoints, an excess of stroke 
events (a labeled risk of Aranesp ther-
apy) occurred in the Aranesp-treated 
patients compared to those receiving 
placebo. ” 7 Th is is not the fi rst time that 
increased risk for cerebrovascular events 
has been found to occur with ESA treat-
ment to higher Hgb targets. 8 But the fact 
that it occurred in a study specifically 
of patients with diabetes, and with 
the greater evidentiary value of an 
RCT, runs counter to the fi ndings of 
Szczech  et al. 1 
 Treatment of anemia in patients with 
CKD and coexisting CHF is a particu-
larly interesting area. Early studies sug-
gested signifi cant benefi t of ESA and iron 
treatment in terms of improved symp-
toms and reduced hospitalization risk. 9 
However, the CHOIR study found that 
among patients randomized to the 
higher Hgb target there was a strong 
trend toward increased risk for hospi-
talization due to CHF (Figure 1). Indeed, 
this is one of the great paradoxes of the 
analysis by Szczech  et al. 1 Th e higher 
Hgb target led to increased hospitaliza-
tion for CHF in the whole study popula-
tion, yet a baseline history of CHF was 
not associated with increased cardiovas-
cular risk with the higher Hgb target! 
This finding defies easy explanation. 
Although we cannot explain this dis-
crepancy, we would like to comment on 
the complexity of ESA treatment among 
patients with concordant CKD and CHF 
(a large and growing population of 
patients). Nephrologists are well aware 
of the oscillating interplay of renal and 
cardiac function in these patients. 
Increased diuresis worsens renal func-
tion but improves breathing and edema; 
reduction in diuretic dose does the 
reverse. Add ESA treatment to this mix 
and things become even more compli-
cated. During active diuresis, hemocon-
centration occurs, and the ESA dose may 
be reduced despite no change in actual 
red-cell mass. When diuretics are held or 
doses reduced, dilution occurs and Hgb 
decreases, and ESA dose may be 
increased despite no actual decrease in 
red-cell mass. Th ere has been little in the 
way of formal study of this phenomenon. 
Mancini  et al. , however, found that ane-
mia in CHF is oft en due to a combina-
tion of true reduction in red-cell mass 
with dilution. 10 From the management 
perspective, nephrologists simply need 
to be sensitive to the eff ects of volume 
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 Figure 1  |  Hospitalizations for congestive heart failure (without renal replacement 
therapy) in the CHOIR study. There was a strong trend (hazard ratio 1.41,  P  =  0.07) toward 
increased risk for hospitalization among patients randomized to the high-hemoglobin-target 
group. (Adapted with permission from ref. 2.) 
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shifts on Hgb concentration, and to 
adjust ESA doses with this additional 
variable in mind. 
 In conclusion, the fi ndings of the inter-
esting analysis by Szczech  et al. 1 should 
be a stimulus for further study. But there 
are no immediate clinical implications of 
this observational analysis. Hgb targets 
during ESA therapy for patients with 
CHF or diabetes mellitus should remain 
consistent with current guidelines. An 
Hgb target of 10 – 12 or 11 – 12 g / dl 
remains a reasonable target that balances 
improved quality of life with potential 
cardiovascular risk. 
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 Over the past few decades, there has been 
a substantial decrease in the incidence of 
hepatitis B virus (HBV) infection in hemo-
dialysis patients, probably attri butable to 
screening of blood donors, a decline in 
blood transfusion requirements with 
increased erythropoietin use, and author-
itative guidelines relating to infection con-
trol and vaccination. Despite this progress, 
hemodialysis patients remain at increased 
risk of acquiring HBV because of increased 
exposure to blood products, shared hemo-
dialysis equipment, frequent breaching of 
skin, immunodefi ciency, and continuing 
high prevalence rates of HBV infection 
among hemodialysis populations. 
Although acute infection tends to be mild 
and asymptomatic in dialysis patients, up 
to two-thirds may progress to chronic car-
riage, with signifi cant risk of chronic liver 
disease,  premature death from cirrhosis or 
liver cancer, and nosocomial transmission 
within hemodialysis units. 1,2 
 When available to healthy individuals, 
HBV vaccination is an extremely eff ec-
tive means of disease prevention. Admin-
istration of three doses of 20   g of HBV 
surface antigen (HBsAg) over 6 months 
achieves seroprotection rates of more 
than 90 % . 2 Alternatively, among chronic 
kidney disease (CKD) populations, 
immune responses to HBV vaccination 
are impaired, proportionally to the 
degree of kidney failure. 1 Hence, CKD 
patients experience lower seroconversion 
rates (32 – 80 % ), lower peak antibody titers, 
and shorter durations of seroprotection 
(protective antibody titers maintained in 
50 % of CKD patients compared with 85 % 
of healthy individuals after 1 year). 2,3 
Strategies to improve response rates 
among such patients have included vac-
cination as early as possible in the course 
of renal disease, use of double vaccine 
dose, and a four-dose rather than three-
dose schedule. 1,2 These have yielded 
some, but still suboptimal, improvement, 
achieving response rates of approxi-
mately 70 % . 3 Th us, additional strategies 
to improve vaccination response remain 
an important and as-yet unmet priority. 
 Th e development of protective immu-
nity following administration of vaccine 
requires the interaction of the innate and 
adaptive immune systems (Figure 1). 
Specifi cally, antigen recognition requires 
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 Hemodialysis patients are at increased risk of acquiring hepatitis B virus 
(HBV) infection. Administration of the standard HBV vaccine is 
suboptimal as a means of prevention because of an impaired 
seroconversion response in individuals with chronic kidney disease. 
Surquin and colleagues describe a novel vaccine adjuvant system that 
increases speed of seroconversion and duration of seroprotection 
compared with older vaccine formulations. However, its ability to 
improve overall seroconversion response remains unproven. 
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